RAPT Therapeutics, Inc. – NASDAQ:RAPT

Add to watchlist

$10.68

+8.99

+531.95%

Market closed

Open in about 1 hour

-50.73%

month

-50.73%

quarter

-93.21%

year

Market Cap	61.70M
Enterprise value	492.64M

P/E	-6.78
EV/Sales	227.23
EV/EBITDA	-5.92
Price/Sales	241.05
Price/Book	2.13
PEG ratio	3.43
EPS	-3.07

Revenue	N/A
EBITDA	-127.38M
Income	-118.04M
Revenue Q/Q	N/A
Revenue Y/Y	246.29%

Profit margin	-3867.07%
Oper. margin	-3957.33%
Gross margin	40.87%
EBIT margin	-3957.33%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

RAPT Therapeutics Stock Forecast

M Q Y

Last Year

Potential downside: -81.27%

Analysts Price target
Financials & Ratios estimates

RAPT Therapeutics, Inc. (NASDAQ:RAPT): Profit margin
Jun 2023	0	-25.28M
Sep 2023	0	-31.37M
Dec 2023	5.28M	-30.87M	-583.89%
Mar 2024	0	-30.52M

RAPT Therapeutics, Inc. (NASDAQ:RAPT): Debt to assets
Jun 2023	220756000	21.07M	9.55%
Sep 2023	199721000	26.92M	13.48%
Dec 2023	173329000	26.29M	15.17%
Mar 2024	155818000	24.98M	16.03%

RAPT Therapeutics, Inc. (NASDAQ:RAPT): Cash Flow
Jun 2023	-28.80M	32.43M	767K
Sep 2023	-21.88M	25.74M	106K
Dec 2023	-27.75M	20.63M	458K
Mar 2024	-27.08M	15.88M	9.03M

RAPT Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

RAPT Therapeutics, Inc. (NASDAQ:RAPT): Employee count
Aug 2023	111
Sep 2023	122
Oct 2023	122
Nov 2023	122
Dec 2023	129
Jan 2024	129
Feb 2024	129
Mar 2024	131
Apr 2024	131
May 2024	131
Jun 2024	126
Jul 2024	126

RAPT Therapeutics
Hedge Funds Holdings Q3 2022

89.65% -9.09%

of RAPT is owned by hedge funds

91 +8

hedge funds hold RAPT stock

27.91M -1.28M

shares is hold by hedge funds

RAPT hedge funds holdings changes

RAPT Therapeutics
Insider Trading

RAPT Therapeutics, Inc. (NASDAQ:RAPT): Insider trades (number of shares)
Period	Buy	Sel
Mar 2023	5000	5000
Apr 2023	0	5000
Aug 2023	0	2500
Oct 2023	0	2500
Nov 2023	0	1500
Dec 2023	0	2500
Jan 2024	0	898

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	5 Jan 2024	BROCKSTEDT DIRK G. officer: CHIEF SC..	Common Stock	898	$22.78	$20,456
Option	29 Dec 2023	BROCKSTEDT DIRK G. officer: Chief Sc..	Common Stock	8,000	$6.18	$49,440
Option	29 Dec 2023	BROCKSTEDT DIRK G. officer: Chief Sc..	Employee Stock Option (right to buy)	8,000	$6.18	$49,440
Sale	21 Dec 2023	HO WILLIAM officer: Chief Me..	Common Stock	2,500	$21.68	$54,200
Sale	28 Nov 2023	HO WILLIAM officer: Chief Me..	Common Stock	1,500	$13.72	$20,580
Sale	3 Oct 2023	HO WILLIAM officer: Chief Me..	Common Stock	2,500	$15.77	$39,425
Sale	18 Aug 2023	HO WILLIAM officer: Chief Me..	Common Stock	2,500	$18.92	$47,300
Option	28 Jul 2023	HO WILLIAM officer: Chief Me..	Common Stock	460	$12	$5,520
Option	28 Jul 2023	HO WILLIAM officer: Chief Me..	Employee Stock Option (right to buy)	460	$12	$5,520
Option	23 Jun 2023	HO WILLIAM officer: Chief Me..	Common Stock	920	$12	$11,040

RAPT insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS OF MAKING TRANS ISOMERIC FORMS OF G PROTEIN-COUPLED RECEPTOR MODULATORS Filling date: 28 Jan 2022 Issue date: 11 Aug 2022	28 Jan 2022	11 Aug 2022
Grant	Grant Utility: Chemokine receptor modulators and uses thereof Filling date: 27 Apr 2020 Issue date: 7 Dec 2021	27 Apr 2020	7 Dec 2021
Application	Application UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF Filling date: 5 Mar 2020 Issue date: 14 Oct 2021	5 Mar 2020	14 Oct 2021
Grant	Grant Utility: Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof Filling date: 20 Sep 2019 Issue date: 10 Aug 2021	20 Sep 2019	10 Aug 2021
Grant	Grant Utility: Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses Filling date: 4 Jun 2019 Issue date: 29 Jun 2021	4 Jun 2019	29 Jun 2021
Application	Application CRYSTALLINE FORMS OF C-C CHEMOKINE RECEPTOR TYPE 4 ANTAGONIST AND USES THEREOF Filling date: 13 Nov 2020 Issue date: 13 May 2021	13 Nov 2020	13 May 2021
Application	Application CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF Filling date: 27 Apr 2020 Issue date: 29 Oct 2020	27 Apr 2020	29 Oct 2020
Application	Application CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF Filling date: 27 Apr 2020 Issue date: 15 Oct 2020	27 Apr 2020	15 Oct 2020
Application	Application CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF Filling date: 28 Jan 2020 Issue date: 30 Jul 2020	28 Jan 2020	30 Jul 2020
Grant	Grant Utility: Chemokine receptor modulators and uses thereof Filling date: 24 Jan 2019 Issue date: 16 Jun 2020	24 Jan 2019	16 Jun 2020

RAPT Therapeutics
Executives

Insider	Age	Compensation
Dr. Brian Russell Wong M.D., Ph.D. (1972) Chief Executive Officer, Pres & Director	53	$687,500
Dr. William Ho (1966) Chief Medical Officer	59	$530,000
Dr. Dirk G. Brockstedt Ph.D. (1969) Chief Scientific Officer	56	$490,250

RAPT Therapeutics
Latest News

Monday, 23 December 2024
07:10	RAPT Therapeutics Announces $150 Million Private Placement	globenewswire.com
Monday, 11 November 2024
10:34	Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury	benzinga.com
Friday, 14 June 2024
10:36	Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround	zacks.com
Wednesday, 29 May 2024
10:35	Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner	zacks.com
Monday, 20 May 2024
04:35	RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity	seekingalpha.com
Monday, 13 May 2024
10:36	Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks	Zacks Investment Research
Tuesday, 9 April 2024
06:31	3 Biotech Stocks to Dump Before They Go to Zero	InvestorPlace
Thursday, 7 March 2024
09:41	Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?	Zacks Investment Research
Tuesday, 20 February 2024
08:36	RAPT Therapeutics' stock plunges as FDA halts two clinical trials	Market Watch
Wednesday, 27 September 2023
21:24	7 ‘Strong Buy' Biotech Stocks to Rejuvenate Your Portfolio	InvestorPlace
Wednesday, 30 August 2023
16:05	RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September	GlobeNewsWire
Tuesday, 13 June 2023
15:59	RAPT Therapeutics: Major Catalysts Are A Long Way Off	Seeking Alpha
Wednesday, 7 June 2023
08:00	RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference	GlobeNewsWire
Thursday, 25 May 2023
17:00	RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers	GlobeNewsWire
Thursday, 30 March 2023
00:12	RAPT Therapeutics: Potential Strong Upside Ahead	Seeking Alpha
Thursday, 23 February 2023
10:33	What Makes Rapt Therapeutics (RAPT) a Good Fit for 'Trend Investing'	Zacks Investment Research
Friday, 10 February 2023
11:18	Wall Street Analysts Think Rapt Therapeutics (RAPT) Could Surge 66.77%: Read This Before Placing a Bet	Zacks Investment Research
Wednesday, 25 January 2023
10:33	Here's Why 'Trend' Investors Would Love Betting on Rapt Therapeutics (RAPT)	Zacks Investment Research
Tuesday, 3 January 2023
08:00	RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference	GlobeNewsWire
Wednesday, 30 November 2022
19:05	RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress	GlobeNewsWire
Tuesday, 22 November 2022
09:47	Why RAPT Therapeutics (RAPT) Stock Might be a Great Pick	Zacks Investment Research
Friday, 23 September 2022
13:32	Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research
Thursday, 1 September 2022
11:34	How Much Upside is Left in Rapt Therapeutics (RAPT)? Wall Street Analysts Think 74%	Zacks Investment Research
Wednesday, 31 August 2022
08:00	RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September	GlobeNewsWire
Wednesday, 11 May 2022
10:32	Rapt Therapeutics (RAPT) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Tuesday, 4 January 2022
08:00	RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference	GlobeNewsWire
Wednesday, 10 November 2021
19:50	Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates	Zacks Investment Research
Monday, 8 November 2021
16:06	Rapt Therapeutics (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release	Zacks Investment Research
Monday, 18 October 2021
08:00	RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit	GlobeNewsWire
Thursday, 30 September 2021
09:15	RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 20 May 2024

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
Seeking Alpha 30 Mar 2023

RAPT Therapeutics: Potential Strong Upside Ahead

Frequently Asked Questions (FAQ)

What's the price of RAPT Therapeutics stock today?

One share of RAPT Therapeutics stock can currently be purchased for approximately $10.68.
When is RAPT Therapeutics's next earnings date?

Unfortunately, RAPT Therapeutics's (RAPT) next earnings date is currently unknown.
Does RAPT Therapeutics pay dividends?

No, RAPT Therapeutics does not pay dividends.
How much money does RAPT Therapeutics make?

RAPT Therapeutics has a market capitalization of 61.70M.
What is RAPT Therapeutics's stock symbol?

RAPT Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "RAPT".
What is RAPT Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of RAPT Therapeutics?

Shares of RAPT Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are RAPT Therapeutics's key executives?
RAPT Therapeutics's management team includes the following people:
- Dr. Brian Russell Wong M.D., Ph.D. Chief Executive Officer, Pres & Director(age: 53, pay: $687,500)
- Dr. William Ho Chief Medical Officer(age: 59, pay: $530,000)
- Dr. Dirk G. Brockstedt Ph.D. Chief Scientific Officer(age: 56, pay: $490,250)
How many employees does RAPT Therapeutics have?

As Jul 2024, RAPT Therapeutics employs 126 workers, which is 4% less then previous quarter.
When RAPT Therapeutics went public?

RAPT Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 31 Oct 2019.
What is RAPT Therapeutics's official website?

The official website for RAPT Therapeutics is rapt.com.
Where are RAPT Therapeutics's headquarters?

RAPT Therapeutics is headquartered at 561 Eccles Avenue, South San Francisco, CA.
How can i contact RAPT Therapeutics?

RAPT Therapeutics's mailing address is 561 Eccles Avenue, South San Francisco, CA and company can be reached via phone at +65 04899000.
What is RAPT Therapeutics stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for RAPT Therapeutics in the last 12 months, the avarage price target is $2. The average price target represents a -81.27% change from the last price of $10.68.

RAPT Therapeutics, Inc.

rapt.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

+65 04899000

561 Eccles Avenue
South San Francisco, CA 94080

CIK: 0001673772
ISIN: US75382E1091
CUSIP: 75382E109